CompletedPhase 3

Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis

Germany57 participantsStarted 2010-05

Plain-language summary

The purpose of this study is to determine whether budesonide or mesalazine is more active in the treatment of lymphocytic colitis.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Signed informed consent * Symptoms and signs of indication of lymphocytic colitis Exclusion Criteria: * Infectious diarrhoea, * Diarrhoea as a result of the presence of other symptomatic organic disease(s) of the gastrointestinal tract or endoscopic-histological findings Celiac disease * Pregnancy or breast-feeding, * Participation in an other clinical trial

What they're measuring

Rate of clinical remission

Timeframe: 8 weeks

Trial details

NCT IDNCT01209208

SponsorDr. Falk Pharma GmbH

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-06

View on ClinicalTrials.gov More Lymphocytic Colitis trials